Literature DB >> 12667668

Humanization of an anti-ICAM-1 antibody with over 50-fold affinity and functional improvement.

Guang X Luo1, Lori A Kohlstaedt, Catherine H Charles, Elliott Gorfain, Ianessa Morantte, Jimmy H Williams, Fang Fang.   

Abstract

The monoclonal antibody 1A6 binds to human intercellular adhesion molecule 1 (ICAM-1, CD54) and inhibits infection by 90% of human rhinovirus (HRV) serotypes. To make a therapeutic molecule for preventing and treating HRV infection, we humanized a single chain antibody (scFv), 1A6, by a structure-guided complementarity-determining region (CDR) grafting procedure. Our final humanized 1A6 scFv does not retain any mouse back mutations in the framework. Without changing the CDR sequences, the humanized 1A6 scFv demonstrates over 50-fold improvement in both affinity for ICAM-1 and protection efficacy against HRV infection in vitro.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12667668     DOI: 10.1016/s0022-1759(02)00542-2

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  10 in total

1.  Design and Generation of Humanized Single-chain Fv Derived from Mouse Hybridoma for Potential Targeting Application.

Authors:  Kannika Khantasup; Warangkana Chantima; Chak Sangma; Kanokwan Poomputsa; Tararaj Dharakul
Journal:  Monoclon Antib Immunodiagn Immunother       Date:  2015-12

2.  Optimizing endothelial targeting by modulating the antibody density and particle concentration of anti-ICAM coated carriers.

Authors:  Andres J Calderon; Tridib Bhowmick; John Leferovich; Bharat Burman; Benjamin Pichette; Vladimir Muzykantov; David M Eckmann; Silvia Muro
Journal:  J Control Release       Date:  2010-11-01       Impact factor: 9.776

3.  Generic approach for the generation of stable humanized single-chain Fv fragments from rabbit monoclonal antibodies.

Authors:  Leo Borras; Tea Gunde; Julia Tietz; Ulrich Bauer; Valérie Hulmann-Cottier; John P A Grimshaw; David M Urech
Journal:  J Biol Chem       Date:  2010-01-07       Impact factor: 5.157

Review 4.  Dynamic factors controlling targeting nanocarriers to vascular endothelium.

Authors:  Vladimir R Muzykantov; Ravi Radhakrishnan; David M Eckmann
Journal:  Curr Drug Metab       Date:  2012-01       Impact factor: 3.731

5.  Prevention of human rhinovirus infection by multivalent fab molecules directed against ICAM-1.

Authors:  Catherine H Charles; Guang X Luo; Lori A Kohlstaedt; Ianessa G Morantte; Elliott Gorfain; Linguang Cao; Jimmy H Williams; Fang Fang
Journal:  Antimicrob Agents Chemother       Date:  2003-05       Impact factor: 5.191

6.  Specific binding of the pathogenic prion isoform: development and characterization of a humanized single-chain variable antibody fragment.

Authors:  Nives Skrlj; Tanja Vranac; Mara Popović; Vladka Curin Šerbec; Marko Dolinar
Journal:  PLoS One       Date:  2011-01-20       Impact factor: 3.240

Review 7.  Biochemical prevention and treatment of viral infections - a new paradigm in medicine for infectious diseases.

Authors:  Hervé Le Calvez; Mang Yu; Fang Fang
Journal:  Virol J       Date:  2004-11-23       Impact factor: 4.099

Review 8.  Vascular targeting of nanocarriers: perplexing aspects of the seemingly straightforward paradigm.

Authors:  Melissa Howard; Blaine J Zern; Aaron C Anselmo; Vladimir V Shuvaev; Samir Mitragotri; Vladimir Muzykantov
Journal:  ACS Nano       Date:  2014-05-07       Impact factor: 15.881

9.  Rational design of antirheumatic prodrugs specific for sites of inflammation.

Authors:  Shimobi C Onuoha; Mathieu Ferrari; Daniele Sblattero; Costantino Pitzalis
Journal:  Arthritis Rheumatol       Date:  2015-10       Impact factor: 10.995

10.  ELISA-Based Assay for Studying Major and Minor Group Rhinovirus-Receptor Interactions.

Authors:  Petra Pazderova; Eva E Waltl; Verena Niederberger-Leppin; Sabine Flicker; Rudolf Valenta; Katarzyna Niespodziana
Journal:  Vaccines (Basel)       Date:  2020-06-18
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.